MARKET

PVLA

PVLA

Palvella Therapeutics Inc
NASDAQ
142.04
-0.54
-0.38%
After Hours: 142.10 +0.06 +0.04% 17:03 08/21 EDT
OPEN
145.55
PREV CLOSE
142.58
HIGH
146.92
LOW
138.54
VOLUME
161.87K
TURNOVER
--
52 WEEK HIGH
161.38
52 WEEK LOW
46.08
MARKET CAP
2.05B
P/E (TTM)
-29.4414
1D
5D
1M
3M
1Y
5Y
1D
Palvella Therapeutics: First Approval Could Unlock A Rare-Disease Commercial Flywheel
Seeking Alpha · 2d ago
Weekly Report: what happened at PVLA last week (0810-0814)?
Weekly Report · 4d ago
Weekly Report: what happened at PVLA last week (0803-0807)?
Weekly Report · 08/10 09:25
Analysts Are Bullish on Top Healthcare Stocks: Palvella Therapeutics (PVLA), Lifecore Biomedical (LFCR)
TipRanks · 08/05 18:00
Palvella Therapeutics price target lowered to $207 from $210 at Truist
TipRanks · 08/05 14:06
Truist Financial Sticks to Its Buy Rating for Palvella Therapeutics (PVLA)
TipRanks · 08/05 13:51
Palvella Therapeutics price target raised to $232 from $227 at Canaccord
TipRanks · 08/05 11:15
Analysts Offer Insights on Healthcare Companies: Henry Schein (HSIC), OrthoPediatrics (KIDS) and Palvella Therapeutics (PVLA)
TipRanks · 08/05 10:30
More
About PVLA
Palvella Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing and commercializing therapies to treat patients suffering from serious, rare genetic skin diseases for which there are no FDA-approved therapies. The Company is developing a pipeline of product candidates based on its patented QTORIN platform, with an initial focus on serious, rare genetic skin diseases, many of which are lifelong in nature. Its QTORIN product candidates are developed to accommodate the cargo at high concentrations in order to drive sufficient drug to its target deep in the epidermis and dermis. The Company's lead product candidate, QTORIN 3.9% rapamycin anhydrous gel (QTORIN rapamycin), is being evaluated in the Phase III SELVA clinical trial in microcystic lymphatic malformations and the Phase II TOIVA clinical trial in cutaneous venous malformations.

Webull offers Palvella Therapeutics Inc stock information, including NASDAQ: PVLA real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, PVLA stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading PVLA stock methods without spending real money on the virtual paper trading platform.